LB54640
- Generic Name
- LB54640
- Drug Type
- Small Molecule
- Background
LB54640 is orally-administered small molecule agonist of the melanocortin 4 receptor.
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Rhythm Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06046443
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity
Phase 2
Not yet recruiting
- Conditions
- LEPR Deficiency ObesityPOMC Deficiency ObesityPCSK1 Deficiency Obesity
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- LG Chem
- Target Recruit Count
- 4
- Registration Number
- NCT06041841
- Locations
- 🇫🇷
Pitié Salpêtrière hospital and Sorbonne Université, Paris, France
🇬🇧Cambridge university, Cambridge, United Kingdom
A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- LG Chem
- Target Recruit Count
- 112
- Registration Number
- NCT06040372
- Locations
- 🇺🇸
Clinical Research Unit, Chula Vista, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath